Search for content, post, videos

Axel Sjöblad is the new CEO of SenzaGen

Axel Sjöblad

The company’s Board has appointed Axel Sjöblad as the new CEO starting June 17, 2019.

Sjöblad most recently held the position as CEO of BioGaia and replaces Anki Malmborg Hager, who after five years as CEO, is nominated to become a member of the company’s board.

“We are pleased to welcome Axel Sjöblad as CEO during this important phase of our growth journey. Axel has solid commercial background in the life science sector and will add valuable expertise through his broad experience of driving sales expansion into international markets. The Board is convinced that Axel has the necessary skills, vision and determination to build on the foundations that CEO Anki Malmborg Hager, has successfully laid in recent years,” says Carl Borrebaeck, Chairman of SenzaGen.

Axel Sjöblad

Axel Sjöblad has extensive experience in managing and developing global growth companies in medical technology and Life Science. During his time as CEO of BioGaia from 2016 to 2018, the company strengthened its market-leading position, with an increased market cap from around SEK 4 billion to approximately SEK 7 billion. Prior to working for BioGaia, Sjöblad was President Sales and Service North Europe and CEO of Getinge Sverige AB and Regional Vice President Northern European Markets at Gambro with responsibility for subsidiaries running operations in several European countries. He holds an MBA and Executive MBA from the Stockholm School of Economics. He is a board member of VibroSense Dynamics and former elite player in handball.

“SenzaGen is a very well-run company that has developed with a long-term and serious focus and I look forward to further leading the company towards full-scale commercialization. The company’s test methods have the potential to fulfill a unique customer need and to promote a paradigm shift for industrial tests. For the first time substances that cause allergies can be identified both with greater accuracy and most importantly without any animal testing. I very much look forward to being a part of this,” says Sjöblad.